Skip to main content
. 2016 Mar 1;18(5):491–499. doi: 10.1111/dom.12639

Figure 1.

DOM-12639-FIG-0001-c

Liraglutide exposure and body weight loss. Liraglutide exposure expressed as model‐derived area under the curve (AUC) at steady‐state versus body weight loss. (A) Exposure versus body weight change from baseline; (B) exposure versus proportion of individuals with ≥5% weight loss from baseline; (C) exposure versus proportion of individuals with >10% weight loss from baseline. Data are mean values (with 95% confidence intervals) versus exposure expressed as six quantiles of area under the curve (AUC) values (plus placebo). Sigmoidal curved lines represent covariate‐adjusted model‐based estimates for each trial population. Horizontal bars with diamonds represent median and 90% exposure ranges from each dose level. Trial 1, SCALE Obesity and Prediabetes; Trial 2, SCALE Diabetes; Trial 3, the phase II trial.